Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yanpin Liu, bachelor
- Phone Number: +861069159088
- Email: liuyp1227@vip.sina.com
Study Contact Backup
- Name: Yixuan Hou, master
- Phone Number: +8618810112590
- Email: 15612494030@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- preparing for pregnancy or early pregnancy women (< 12w)
- no major surgery, trauma, or important viscera disease
- no long-term medication history
- No serious mental and psychological behavior abnormalities
- resident in Beijing, can accept regular prenatal in Beijing area
- signed informed consent
Exclusion Criteria:
- have taken medications that may affect the metabolism of nutrients, but are unable to provide their ingredients or doses, making it difficult to judge their effects
- From the first three months of this pregnancy to the time of inclusion, taking drugs that interfere with the absorption, metabolism, and utilization of nutrients.
- From the first three months of this pregnancy to the time of inclusion, Pregnant woman took iron, selenium, vitamin B6, vitamin B12, vitamin D preparations, and the dosage was higher than the corresponding physiological standard.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Normal iron
|
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d).
The second stage lasts for 4 weeks.
For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d).
The second stage lasts for 4 weeks.
For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
|
|
EXPERIMENTAL: Weak iron
|
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d).
The second stage lasts for 4 weeks.
For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d).
The second stage lasts for 4 weeks.
For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
|
|
EXPERIMENTAL: Normal selenium
|
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d).
The second stage lasts for 4 weeks.
For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d).
The second stage lasts for 4 weeks.
For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
|
|
EXPERIMENTAL: Weak selenium
|
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d).
The second stage lasts for 4 weeks.
For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d).
The second stage lasts for 4 weeks.
For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention.
For those with good nutritional status, the dietary recommendation amount is maintained.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between the results of nutritional evaluation of selenium-related genes and selenium levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of selenium gene monitoring and the levels of selenium in vivo
|
lasted for 4 weeks
|
|
Correlation between the results of nutritional evaluation of iron-related genes and iron levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of iron gene monitoring and the levels of iron in vivo
|
lasted for 4 weeks
|
|
Correlation between the results of nutritional evaluation of vitamin B6-related genes and vitamin B6 levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of vitamin B6 gene monitoring and the levels of vitamin B6 in vivo
|
lasted for 4 weeks
|
|
Correlation between the results of nutritional evaluation of vitamin B12-related genes and vitamin B12 levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of vitamin B12 gene monitoring and the levels of vitamin B12 in vivo
|
lasted for 4 weeks
|
|
Correlation between the results of nutritional evaluation of vitamin D-related genes and vitamin D levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of vitamin D gene monitoring and the levels of vitamin D in vivo
|
lasted for 4 weeks
|
|
Correlation between the results of nutritional evaluation of pantothenic acid-related genes and pantothenic acid levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of pantothenic acid gene monitoring and the levels of pantothenic acid in vivo
|
lasted for 4 weeks
|
|
Correlation between gestational diabetes-related gene monitoring results and glycosylated hemoglobin,fasting blood glucose, fasting insulin levels in vivo
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of gestational diabetes-related gene monitoring and the levels of glycosylated hemoglobin,fasting blood glucose, fasting insulin in vivo
|
lasted for 4 weeks
|
|
Correlation between gestational hypertension-related gene monitoring results and homocysteine, serum folic acid and RBC Folate levels in vivo
Time Frame: lasted for 4 weeks
|
TThe correlation between the nutrition evaluation results of gestational hypertension-related gene monitoring and the levels of homocysteine, serum folic acid and RBC Folate in vivo
|
lasted for 4 weeks
|
|
Correlation between hyperlipidemia-related gene monitoring results and the level of plasma lipid in vivo.
Time Frame: lasted for 4 weeks
|
The correlation between the nutrition evaluation results of hyperlipidemia-related gene monitoring and the levels of plasma lipid in vivo
|
lasted for 4 weeks
|
|
nutritional status
Time Frame: lasted for 4 weeks
|
The nutritional status of selenium was compared between the normal selenium and week selenium group; The nutritional status of iron was compared between the normal iron and the weak group.
Meanwhile, compare the selenium and iron nutritional status of the four groups before and after the intervention.
|
lasted for 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- hs-1646
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.